Table 1.
Demographic, Hospital and Treatment Characteristics of Patients with Pathologically Confirmed Small Cell Lung Cancer, by Extent of Disease (N=931)
| Demographics | Limited Stage Disease | Extensive Stage Disease | p-Value |
|---|---|---|---|
|
| |||
| (N=288) N, Wt % | (N=643) N, Wt % | ||
|
| |||
| Age at diagnosis | 0.13 | ||
| <60 | 59 (24.1) | 156 (25.5) | |
| 60–69 | 85 (36.6) | 201 (32.3) | |
| 70–79 | 106 (32.5) | 209 (30.5) | |
| ≥80 | 38 (6.8) | 77 (11.6) | |
|
| |||
| Sex | 0.2 | ||
| Male | 146 (45.1) | 337 (52.4) | |
| Female | 142 (54.9) | 306 (47.6) | |
|
| |||
| Race/Ethnicity | 0.34 | ||
| White | 121 (81.2) | 295 (84.1) | |
| Black | 74 (8.5) | 174 (8.0) | |
| Hispanic | 49 (5.3) | 102 (4.5) | |
| Other/Unknown | 44 (5.0) | 72 (3.4) | |
|
| |||
| Insurance | 0.35 | ||
| Private | 141 (57.3) | 347 (59.8) | |
| Any Medicaid | 80 (17.8) | 152 (18.3) | |
| Medicare only | 45 (16.7) | 103 (13.4) | |
| IHS/Tricare/VA/Military | 12 (6.0) | 14 (3.1) | |
| Unknown/No Insurance | 10 (2.2) | 27 (5.4) | |
|
| |||
| Smoking Status | 0.56 | ||
| Current | 124 (50.2) | 319 (53.3) | |
| Previous | 129 (43.0) | 259 (38.1) | |
| Never/Unknown | 35 (6.8) | 65 (8.6) | |
|
| |||
| Charlson Comorbidity Score | 0.32 | ||
| 0 | 115 (40.8) | 257 (33.8) | |
| 1 | 109 (37.4) | 261 (46.2) | |
| ≥2 | 64 (21.8) | 125 (20.0) | |
|
| |||
| Pneumonia/Lung Collapse | 0.94 | ||
| Yes | 110 (42.4) | 264 (42.8) | |
| No/Unknown | 178 (57.6) | 379 (57.2) | |
|
| |||
| Treating Hospital Characteristics | |||
|
| |||
| Bed Size | 0.37 | ||
| <199 | 68 (26.1) | 124 (23.5) | |
| 200–299 | 64 (19.9) | 168 (28.4) | |
| 300–399 | 72 (21.8) | 132 (18.8) | |
| 400+ | 77 (29.3) | 202 (25.5) | |
| Unknown/Outpatient | 7 (2.9) | 17 (3.8) | |
|
| |||
| Approved Residency Training Program | 1.0 | ||
| Yes | 130 (41.4) | 322 (41.4) | |
| No/Unknown | 158 (58.6) | 321 (58.6) | |
|
| |||
| Hospital Ownership | 0.03 | ||
| For Profit | 27 (10.7) | 62 (8.9) | |
| Not-for-Profit | 195 (62.7) | 445 (76.1) | |
| Government/Other | 66 (26.7) | 136 (15.0) | |
|
| |||
| Therapy | |||
|
| |||
| Treatment | <0.0001 | ||
|
| |||
| Etoposide with Cis or Carbo-platin | 27 (12.0) | 215 (30.2) | |
|
| |||
| Other Chemotherapy* | 8 (2.5) | 76 (9.8) | |
|
| |||
| Thoracic Radiation Only | 10 (3.2) | 17 (2.1) | |
|
| |||
| Etoposide with Cis or Carbo-platin & Thoracic Radiation | 159 (59.5) | 113 (18.8) | |
|
| |||
| Other Chemotherapy *& Thoracic Radiation | 33 (12.7) | 32 (6.3) | |
|
| |||
| Refused Treatment | 13 (2.1) | 33 (3.4) | |
|
| |||
| No/Unknown Treatment | 38 (8.0) | 157 (29.4) | |
|
| |||
| Clinical Trial Participant | 0.16 | ||
|
| |||
| Registered | 2 (0.2) | 9 (0.6) | |
|
| |||
| Pet Scan Received | 0.004 | ||
|
| |||
| Yes | 111 (43.0) | 171 (26.4) | |
|
| |||
| No/Unknown | 177 (57.0) | 472 (73.6) | |
Wt: Weighted to the population from which the sample was drawn
*
Note: Other chemotherapy regimens were defined failure to receive a combination of Cisplatin or Carboplatin with Etoposide